Testosterone Treatment Lawsuits Continue to Mount, With Filing of New AndroGel Lawsuit in Illinois Federal Court, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating testosterone treatment lawsuits on behalf of individuals who allegedly suffered heart attacks, strokes, deep vein thrombosis, and pulmonary embolism due to their use of prescription “Low T” therapies like AndroGel.

Free Case Review
We expect that the number of testosterone lawsuit filings involving AndroGel and similar drugs will continue to mount in the coming months.

Testosterone treatment lawsuits (http://www.testosteronelawsuitcenter.com/) involving prescription medications like AndroGel continue to mount in courts throughout the country, Bernstein Liebhard LLP reports. According to court documents, a new AndroGel lawsuit was recently filed in the U.S. District Court, Northern District of Illinois, on behalf of a man who allegedly suffered a pulmonary embolism and deep vein thrombosis after using multiple doses of the medication. The complaint, which is dated February 10, 2014, alleges AndroGel can cause hematocrit levels to increase, thereby thickening the blood and leading to pulmonary embolism, deep vein thrombosis, and other serious cardiovascular injuries. (Case: 1:14-cv-00917)

“Since the FDA announced last month that it was reviewing the safety of prescription testosterone therapies, we have heard from a number of men who have allegedly suffered injuries similar to those put forth by this plaintiff. We expect that the number of testosterone lawsuit filings involving AndroGel and similar drugs will continue to mount in the coming months,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to anyone who may have suffered serious heart attacks, strokes, deep vein thrombosis or pulmonary embolism, allegedly due to the use of prescription testosterone therapies.

Testosterone Lawsuits

The U.S. Food & Drug Administration (FDA) announced on January 31, 2014, that it had launched a safety review of prescription drugs approved to treat low testosterone (Low T) levels in men. The agency decided to act after two studies reported an increase in the risk of serious cardiovascular events in certain men who used these treatments. One of those studies was published last November in the Journal of the American Medical System, and noted an increased risk of heart attack, stroke and death among older men with pre-existing heart problems.* A second study, which was published in PLOS One in January, reported that such treatments ware associated with a doubling of the heart attack risk among younger men with pre-existing heart problems, and in men over 65 regardless of their heart health.**

Since the FDA announcement, court documents show that a number of testosterone lawsuits have been filed in the Northern District of Illinois on behalf of men who were allegedly injured by AndroGel. These include four cases filed on February 4th which accuse the manufacturers of the medication of engaging in marketing that prompted men to seek testosterone therapy for symptoms normally associated with aging, such as fatigue and low libido. As a result, the lawsuits claim that Low T therapies are often prescribed to men who have normal testosterone levels, even though the FDA has only approved these medications for those who suffer from reduced testosterone due to an underlying medical condition. (Case Nos: 1:14-cv-00776, 1:14-cv-00780, 1:14-cv-00777, and 1:14-cv-00772)

Men who allegedly suffered life-threatening heart side effects due to their use of AndroGel and other Low T therapies may be entitled to compensation for their injury-related damages. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*jama.jamanetwork.com/article.aspx?articleid=1764051, JAMA, November 2013
**plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, PLOS One, January 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website